Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1957 1
1963 1
1964 4
1968 1
1969 1
1970 1
1971 4
1972 2
1974 3
1975 1
1976 1
1977 1
1978 2
1981 1
1982 5
1983 1
1984 3
1985 3
1988 4
1993 1
1995 1
1996 5
1997 4
1998 1
2000 4
2001 5
2002 7
2003 8
2004 9
2005 14
2006 9
2007 9
2008 4
2009 8
2010 4
2011 13
2012 10
2013 20
2014 17
2015 13
2016 20
2017 27
2018 25
2019 29
2020 39
2021 29
2022 26
2023 29
2024 22
2025 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Results by year

Filters applied: . Clear all
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
SEOM guidelines 2018.
Santaballa A, Vera R. Santaballa A, et al. Among authors: vera r. Clin Transl Oncol. 2019 Jan;21(1):1-2. doi: 10.1007/s12094-018-02024-4. Epub 2019 Jan 9. Clin Transl Oncol. 2019. PMID: 30627983 No abstract available.
In-hospital stroke.
Masjuan J, Vera R. Masjuan J, et al. Among authors: vera r. Eur J Neurol. 2009 May;16(5):549-50. doi: 10.1111/j.1468-1331.2009.02533.x. Eur J Neurol. 2009. PMID: 19405182 No abstract available.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Understanding LAG-3 Signaling.
Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernández-Rubio L, Morente P, Fernández-Hinojal G, Echaide M, Garnica M, Ramos P, Vera R, Kochan G, Escors D. Chocarro L, et al. Among authors: vera r. Int J Mol Sci. 2021 May 17;22(10):5282. doi: 10.3390/ijms22105282. Int J Mol Sci. 2021. PMID: 34067904 Free PMC article. Review.
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.
Chocarro L, Blanco E, Fernandez-Rubio L, Garnica M, Zuazo M, Garcia MJ, Bocanegra A, Echaide M, Johnston C, Edwards CJ, Legg J, Pierce AJ, Arasanz H, Fernandez-Hinojal G, Vera R, Ausin K, Santamaria E, Fernandez-Irigoyen J, Kochan G, Escors D. Chocarro L, et al. Among authors: vera r. EMBO Mol Med. 2024 Aug;16(8):1791-1816. doi: 10.1038/s44321-024-00098-y. Epub 2024 Jul 19. EMBO Mol Med. 2024. PMID: 39030301 Free PMC article.
Clinical landscape of LAG-3-targeted therapy.
Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, Bocanegra A, Echaide M, Garnica M, Ramos P, Fernández-Hinojal G, Vera R, Kochan G, Escors D. Chocarro L, et al. Among authors: vera r. Immunooncol Technol. 2022 Mar 17;14:100079. doi: 10.1016/j.iotech.2022.100079. eCollection 2022 Jun. Immunooncol Technol. 2022. PMID: 35755891 Free PMC article. Review.
Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.
Labiano I, Huerta AE, Alsina M, Arasanz H, Castro N, Mendaza S, Lecumberri A, Gonzalez-Borja I, Guerrero-Setas D, Patiño-Garcia A, Alkorta-Aranburu G, Hernández-Garcia I, Arrazubi V, Mata E, Gomez D, Viudez A, Vera R. Labiano I, et al. Among authors: vera r. Sci Rep. 2024 Jul 13;14(1):16203. doi: 10.1038/s41598-024-67235-y. Sci Rep. 2024. PMID: 39003322 Free PMC article.
KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis.
Sigafoos AN, Tolosa EJ, Carr RM, Fernandez-Barrena MG, Almada LL, Pease DR, Hogenson TL, Raja Arul GL, Mousavi F, Sen S, Vera RE, Marks DL, Flores LF, LaRue-Nolan KC, Wu C, Bamlet WR, Vrabel AM, Sicotte H, Schenk EL, Smyrk TC, Zhang L, Rabe KG, Oberg AL, Zaphiropoulos PG, Chevet E, Graham RP, Hagen CE, di Magliano MP, Elsawa SF, Pin CL, Mao J, McWilliams RR, Fernandez-Zapico ME. Sigafoos AN, et al. Among authors: vera re. Cancer Res Commun. 2024 Jul 1;4(7):1677-1689. doi: 10.1158/2767-9764.CRC-23-0464. Cancer Res Commun. 2024. PMID: 38896052 Free PMC article.
Omics Approaches in Pancreatic Adenocarcinoma.
González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. González-Borja I, et al. Among authors: vera r. Cancers (Basel). 2019 Jul 25;11(8):1052. doi: 10.3390/cancers11081052. Cancers (Basel). 2019. PMID: 31349663 Free PMC article. Review.
420 results